Across TCGA pan-cancer cohorts, EMILIN3 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated EMILIN3 data layer compared with 25 for mass-spec protein and 6 for mutation status.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher EMILIN3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EMILIN3 expression acts as an unfavorable survival marker.
UCEC and GBM are the cancer types where EMILIN3 mass-spec protein most reproducibly stratifies survival.